GlaxoSmithKline wants to sell more than a third of the space at its R&D campus in Stevenage, UK, to a new bioscience cluster that it says could become one of the largest in Europe.

It will allow swift transport links to GSK's main R&D campus in Stevenage – where the company is also developing a new bioscience cluster – and will also be close to its artificial ...

The GSK Stevenage STEM committee is hosting our 4-day on-site work experience again this year. *Monday 28th July to Thursday 31st July 2025* THE APPLICATION PROCESS IS NOW OPEN! GSK's ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa ...

GSK GSK2.35%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...

GSK has announced that it will be acquiring Boston Pharmaceuticals’ phase 3-ready liver disease candidate in a deal worth up to $2bn. Efimosfermin alfa is an investigational drug in clinical ...

The FDA has lifted its 19-month clinical hold on vaginal yeast infection drug Brexafemme (ibrexafungerp), according to the treatment's developer Scynexis. In its first-quarter report, the Jersey ...

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) recorded EGP 59.123 million in consolidated net profits after tax and non-controlling interest in the first quarter (Q1) of 2025, against EGP 8.99 ...

The committee probe comes after a Wall Street Journal report that British drugmaker GSK approached federal prosecutors with a disputed allegation that a former Pfizer executive who came to work ...